Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview - US, South #1

Report
12 Pages
February 2019
Region: United States
Citeline
ID: 4775340

Overview
This interview covers hepatocellular carcinoma treatment trends in the US.

We discuss current treatment options including the recently approved Keytruda and Lenvima.

Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€579EUR$599USD£498GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€2837EUR$2,935USD£2,439GBP

Related Topics

Related Reports

The American Cancer Society's Oncology in Practice. Clinical Management. Edition No. 1

Global Epidemiology of Cancer. Diagnosis and Treatment. Edition No. 1

Hepatology: An Update, An Issue of Medical Clinics of North America. The Clinics: Internal Medicine Volume 107-3

Global Hand Surgery: Learning and Contributing in Low- and Middle-Income Countries. The Clinics: Orthopedics Volume 35-4

Photomedicine Technology Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F